FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

12 letters match. Newest first.

  1. Chongqing Qiancan Technology Co., Ltd.

    Chongqing Qiancan Technology, an API maker in China, refused FDA records requests; FDA placed its drugs on import alert 66-79.

    High risk
  2. Tianjin Healthcare Medical Technology Co., Ltd.

    Chinese API maker refused FDA records requests, and all its drugs now face a US import alert.

    High risk
  3. Guangdong Bisutang Biotechnology Co., Ltd.

    Guangdong Bisutang Biotechnology refused FDA records requests for OTC drugs and used a cancelled color additive in sunscreen.

    High risk
  4. Suretec Innovations, LLC

    Suretec Innovations failed manufacturing quality rules for OTC sanitizing wipes and did not list a private-label wipe.

    High risk
  5. Skytron, LLC

    Skytron marketed four UV disinfection devices without FDA clearance or approval and kept unapproved medical claims after promising to remove them.

    High risk
  6. InvaDerm, Inc.

    Electronic Drug Registration and Listing System (eDRLS)/Violations

  7. Aeroflex Industria de Aerosol Ltda.

    Brazil OTC drug maker Aeroflex ignored FDA records requests, prompting possible approval holds and US shipment refusals.

    High risk
  8. Aversa's Italian Bakery

    FDA warns Aversa's Italian Bakery over missing food safety plan and undeclared sesame/milk allergens in ready-to-eat rolls.

    High risk
  9. A TO Z Distributor Inc

    FDA warns Brooklyn food importer A TO Z Distributor for having no foreign supplier verification program for any imported food.

    Medium
  10. NSE Products, Inc. DBA Nu Skin Enterprises, Inc.

    Electronic Drug Registration and Listing System (eDRLS)/Violations

  11. Prodose, Inc. formerly known as Spirit Pharmaceuticals LLC

    Electronic Drug Registration and Listing System (eDRLS)/Violations

  12. Grimann S.A. de C.V.

    Failure to Comply with Drug Registration and Listing Requirements